Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript

John Leonard: David?

David Lebwohl: Yeah, the idea of enrolling more advanced patients is that these are the patients who can really benefit from the therapy. If you imagine some of the studies we’ve seen, some patients who are — can be quite healthy despite having some early heart failure and those patients have very few events and therefore contribute very little to the findings in the study. So that’s the idea of doing that. And we do think a positive HELIOS-B study is a positive for us as well, it would show that TTR reduction is a value to patients with cardiomyopathy, but the hypothesis that really all the experts really believe in. So we do think as well that it’s very likely that HELIOS will be positive. The physicians are already very excited about our therapy so that first of all they have seen that we have a very consistent and deeper reduction in TPR.

It could be the best in class agent. So we expect the enrollment to be brisk in any case. Of course having a positive study demonstrating the TTR reduction is important, maybe for — maybe a further value in driving our enrollment as well.

Jack Allen: Great, thanks so much for the color.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Ian Karp for any closing remarks.

Ian Karp: Great, thanks so much, Drew. And thank you everyone for joining us this morning. It’s certainly been an eventful and successful start to the year and we look forward to updating you throughout the year with additional progress. So thanks again and look forward to talking with everyone soon.

Operator: Thank you. The conference has come to a close. You may disconnect your line. Thank you.